Walter P. Maksymowych MB ChB, FACP, FRCP(C)

Walter P. Maksymowych, MB ChB, FRCP(C), FACP, is a Professor, Clinician, and Medical Scientist in the Department of Medicine, Division of Rheumatology at the University of Alberta, Edmonton, Canada. He is Canadian Royal College and American Board of Internal Medicine certified in Internal Medicine and Rheumatology. He is the 2012 recipient of the Distinguished Investigator Award from the Canadian Rheumatology Association. He founded CARE Arthritis Limited, a Canadian company focused on the development of personalized medicine strategies for patients with arthritis, and now serves as Chief Medical Officer.

Dr. Maksymowych graduated from the University of Manchester School of Medicine, United Kingdom, in 1981 and completed his postgraduate training at the Universities of Alberta, Canada, and Cincinnati, USA. His primary research interests are the imaging and treatment of spondyloarthritis, and the clinical validation of biomarker technologies for rheumatic diseases. He has published over 400 research articles and is an active member of numerous international societies related to arthritis. He is developer of the SPARCC MRI scoring systems for inflammation and structural damage in the sacroiliac joints and spine that are now industry standard in clinical trials. Most recently, he co-invented the 14-3-3 biomarker which is now licensed for diagnostic testing of patients with rheumatoid arthritis.